Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$73.31 - $134.63
Previous CloseN/A
Volume3.30M
Average Volume (3M)14.01M
Market Cap
$203.29B
Enterprise Value$298.92B
Total Cash (Recent Filing)$9.23B
Total Debt (Recent Filing)$34.84B
Price to Earnings (P/E)11.8
Beta0.36
Next Earnings
Jul 29, 2025EPS Estimate
2.06Last Dividend Ex-Date
Jun 16, 2025Dividend Yield4.14%
Share Statistics
EPS (TTM)2.22
Shares Outstanding2,511,031,300
10 Day Avg. Volume13,736,294
30 Day Avg. Volume14,006,951
Financial Highlights & Ratios
PEG Ratio1.75
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio19.10
Enterprise Value/Market Cap1.47
Enterprise Value/Revenue1.18
Enterprise Value/Gross Profit5.78
Enterprise Value/Ebitda3.17
Forecast
1Y Price Target
$100.73Price Target Upside27.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMRK announced positive topline results from two Ph3 clinical trials, evaluating enlicitide decanoate (oral PCSK9 inhibitor) for the treatment of adults with hyperlipidemia on lipid-lowering therapies.
Drug PricingManagement characterized discussions with the administration on drug pricing as very constructive, indicating a willingness to find solutions together with the industry.
Oncology StrategyManagement reiterated the sizing of a >$25bn commercial opportunity by the mid-2030’s from the late-phase oncology pipeline across tumor types.
Bears Say
Gardasil Dosing ConcernsThere were concerns on Gardasil after the last ACIP meeting, where the HPV Work Group proposed lowering current dosing recommendations.
Gardasil Franchise UncertaintyUncertainty around Merck's Gardasil franchise and post-Keytruda growth pressures shares.
Near-Term GrowthQuestions remain on near-term growth despite historic success.
Ownership Overview
0.05% Insiders
21.33% Mutual Funds
14.80% Other Institutional Investors
40.27% Public Companies and Individual Investors
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $73.31 and its highest was $134.63 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $203.29B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Jul 29, 2025 which is in 40 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Apr 24, 2025. The company reported $2.22 earnings per share for the quarter, beating the consensus estimate of $2.133 by $0.087.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 4.14%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.06.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,511,031,300 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.22 in its last earnings report, beating expectations of $2.133. Following the earnings report the stock price went up 1.398%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$100.73 (27.04% Upside)
$100.73 (27.04% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 91%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 9.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $352.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.53%
12-Months-Change
Fundamentals
Return on Equity
39.31%
Trailing 12-Months
Asset Growth
8.76%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
MRK Company Deck
MRK Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced view with strong emphasis on future growth potential through a robust pipeline and key product launches, while addressing challenges such as declining Gardasil sales in China and the impact of tariffs and foreign exchange. While there are significant growth drivers, the lowlights indicate notable challenges that could affect near-term performance.Read More>MRK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
MRK Stock 12 Month Forecast
Average Price Target
$100.73
▲(27.04%Upside)